MedPath

Platelet-rich Plasma for Low Back Pain

Not Applicable
Completed
Conditions
Platelet-rich Plasma
Discogenic Pain
Registration Number
NCT03197415
Lead Sponsor
Pei-Yuan Lee, MD
Brief Summary

This study aims to evaluate the effect of platelet-rich plasma (PRP) on discogenic low back pain by comparing the pre- and post-interventional outcomes in patients receiving intradiscal injection of autologous PRP.

Detailed Description

Intervertebral disc (IVD) degeneration is an important clinical problem that often contributes to low back pain and degenerative disc diseases. Degeneration of the IVD induces anulus tears and fissures, which can cause severe discogenic low back pain. Because the IVD has little potential to self-regenerate, treatment of degenerative disc disease is one of the most challenging clinical problems facing the spine surgeon. Platelet-rich plasma (PRP) is a fraction of plasma that contains platelets and multiple growth factors concentrated at high level. Because activated platelets have the potential to release growth factors, PRP has been clinically used to accelerate wound healing and tissue regeneration in orthopedic and oral surgery. The soluble releasate isolated from PRP has recently been demonstrated to influence the metabolism of intervertebral discs in vitro. Furthermore, an intradiscal injection of autologous PRP has been shown to induce restoration of structural changes in the rabbit annular injection model in vivo. This clinical trial aims to investigate the safety and efficacy of intradiscal PRP injection in patients with discogenic low back pain. The pre- and post-interventional imaging and clinical outcomes will be compared.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Age between 20 and 60 years
  • L-spine disc degeneration diagnosed by MRI
  • Low back pain
Exclusion Criteria
  • Herniated disc
  • With prior history of spine surgery
  • With current or prior history of cancer
  • With current or prior history of hematological disease
  • Pregnancy
  • Patients who will not cooperate with one-year followup

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
1-month postoperative function evaluated by Oswestry Disability Index1-month postoperative

Function is evaluated using Oswestry Disability Index.

Secondary Outcome Measures
NameTimeMethod
1-month postoperative pain evaluated by visual analogue scale1-month postoperative

Pain is evaluated using visual analogue scale

4-month postoperative pain evaluated by visual analogue scale4-month postoperative

Pain is evaluated using visual analogue scale

4-month postoperative function evaluated by Oswestry Disability Index4-month postoperative

Function is evaluated using Oswestry Disability Index

Trial Locations

Locations (1)

Show Chwan Memorial Hospital

🇨🇳

Changhua City, Changhua, Taiwan

Show Chwan Memorial Hospital
🇨🇳Changhua City, Changhua, Taiwan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.